Andere Sprachen Celcuity Inc.

Aktien

A2JAAX

US15102K1007

CELC

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 13.05.2024			% 5 Tage	% 1. Jan.
16,77 ^USD	-0,36 %		-6,00 %	+15,10 %

28.03.	CELCUITY INC. : Craig-Hallum bleibt bei seiner Kaufempfehlung	ZM
28.03.	CELCUITY INC. : erhält Kaufen-Rating von Needham & Co.	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call	08.05.
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences	04.04.
Celcuity Inc. Enters into Second Amendment to its Existing Loan and Security Agreement	29.03.
Celcuity Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	27.03.
Celcuity Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27.03.
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call	20.03.
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024	06.03.
Celcuity to Participate in Cowen’s 44th Annual Health Care Conference	28.02.
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer	22.02.
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer	22.02.
Celcuity Appoints Eldon Mayer as Chief Commercial Officer	20.02.
Celcuity Appoints Eldon Mayer as Chief Commercial Officer	20.02.
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium	06.12.
Celcuity Inc. Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium	06.12.
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium	01.12.
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference	22.11.
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates	13.11.
Celcuity Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
North American Morning Briefing : Stock Futures Dip as Inflation Data Looms	13.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Celcuity Inc.

Aktien

A2JAAX

US15102K1007

CELC

Andere Sprachen

Filter